The House Select Committee on China revealed that five leading pharmaceutical manufacturers have pledged to avoid establishing new clinical trials at facilities tied to the Chinese military. The shift follows an inquiry initiated last June examining Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb. Lawmakers opened the probe due to concerns spanning intellectual property risks, ethical practices, and military entanglements in sensitive regions. All five investigated corporations agreed to stop opening studies at these military-connected Chinese sites.
Key points
Lawmakers investigated pharmaceutical firms over concerns regarding national security, in…: Lawmakers investigated pharmaceutical firms over concerns regarding national security, intellectual property vulnerabilities, and research ethics.
All five targeted pharmaceutical companies agreed to cease launching clinical trials at m…: All five targeted pharmaceutical companies agreed to cease launching clinical trials at medical centers affiliated with the Chinese military.
Future clinical research operations by these major drug manufacturers will bypass sensiti…: Future clinical research operations by these major drug manufacturers will bypass sensitive Chinese regions and military-run facilities.
Sources checked by our analysis pipeline: 1
A few of the largest pharmaceutical companies have told a Congressional committee that they do not plan to start new clinical trial sites in the Xinjiang region of China or at hospitals affiliated with the Chinese military.
The disclosure was made by the House Select Committee on China, which last June opened investigations into five companies — Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb — over concerns about intellectual property exposure, military entanglements, and ethical standards at trial sites in sensitive regions of the country.
All five companies indicated they would not initiate new clinical studies at sites linked to the People’s Liberation Army, which is the military wing of the Chinese Communist Party. In letters sent to the drugmakers, the House committee noted rising concern over the possibility of security risks.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
University of California, Berkeley researchers have discovered that the molecule TOFA drives weight loss by raising energy expenditure instead of curbing appetite. This metabolic approach provides a critical alternative to popular therapies that frequently cause patients to lose significant lean muscle mass. If successfully translated to humans, the therapy could substantially improve outcomes for conditions like obesity, diabetes, and fatty liver disease.
Persistent regional outbreaks have stripped multiple nations of their measles-free designations, prompting renewed public health scrutiny regarding community protection levels. Despite the shift in national status, medical guidance confirms that standard two-dose regimens continue to offer lifelong defense for the general population. Additional immunization measures are strictly targeted at specific demographic cohorts and vulnerable individuals facing elevated exposure risks.
Researchers have observed substantial disease control in advanced pancreatic cancer patients by combining a targeted daily medication with standard chemotherapy. The therapy works by deactivating specific genetic mutations that fuel tumour development across multiple difficult-to-treat cancers. While regulatory clearance has already been granted in the US, clinicians stress that extended trials are still essential to determine long-term survival impacts.